Clinical Trial Update: Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF [Phase 3]

View source ↗

Summary

Open-label extension study of oral treprostinil in pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF) terminated; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension Associated with Hfpef

Drugs mentioned

• Treprostinil (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension Associated With HFpEF | Phase 3 | Status: TERMINATED | Results posted: 2020-10-22